Dorsal-ventral patterned neural cyst from human pluripotent stem cells in a neurogenic niche

Y. Zheng1,2*, X. Xue1*, A. M. Resto-Irizarry1, Z. Li1, Y. Shao1, Y. Zheng1, G. Zhao2,3†, J. Fu1,4,5†

Despite its importance in central nervous system development, development of the human neural tube (NT) remains poorly understood, given the challenges of studying human embryos, and the developmental divergence between humans and animal models. We report a human NT development model, in which NT-like tissues, neuroepithelial (NE) cysts, are generated in a bioengineered neurogenic environment through self-organization of human pluripotent stem cells (hPSCs). NE cysts correspond to the neural plate in the dorsal ectoderm and have a default dorsal identity. Dorsal-ventral (DV) patterning of NE cysts is achieved using retinoic acid and/or sonic hedgehog and features sequential emergence of the ventral floor plate, P3, and pMN domains in discrete, adjacent regions and a dorsal territory progressively restricted to the opposite dorsal pole. This hPSC-based, DV patterned NE cyst system will be useful for understanding the self-organizing principles that guide NT patterning and for investigations of neural development and neural disease.

INTRODUCTION

Neurulation is the embryonic process that begins with specification of the neural plate containing neuroepithelial (NE) cells at the dorsal ectoderm germ layer, which then folds in upon itself toward the dorsal side of the embryo to form a tubular structure, the neural tube (NT), enclosing a central fluid-filled lumen. The posterior region of the NT gives rise to the spinal cord, whereas the anterior region becomes the brain, which together comprise the central nervous system (CNS). A very important process during neurulation is the progressive specification of the NT along the dorsal-ventral (DV) axis, that is, DV patterning of the NT (1, 2), which leads to the differentiation of distinct classes of neuronal progenitor cells located at defined positions within the NT. In recent years, tremendous progress has been achieved in understanding the molecular mechanism(s) of DV patterning of the NT using model organisms. It becomes appreciated that the allocation of neuronal fate in the NT is directed by secreted inductive factors (i.e., morphogens) emanated from local surrounding tissues (1, 2). Thus, the position of progenitor cells in the NT influences their fate by defining the identity and concentration of inductive signals to which they are exposed. However, in the ultimate quest to understand the mechanism(s) of human NT development with the goal to prevent and treat developmental defects in the human CNS, studies using model systems remain suboptimal, given substantial interspecies divergence (3). This limitation is further compounded by limited accessibility to the in utero post-implantation mammalian embryo for experimental studies.

Human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs), have been successfully used for modeling post-implantation human embryonic development (4–9). These stem cell–based human development models provide promising experimental systems to study early neural development in humans, as neural cells derived in vitro from hPSCs display molecular and functional properties compatible to those in the developing embryonic brain (10). Technological advances in three-dimensional (3D) hPSC cultures have further led to the development of self-organized, multicellular neuronal tissues, termed brain organoids, that resemble the cerebral cortex, midbrain, and many other brain regions (11). A 3D, DV patterned NT model has recently been reported in a pioneering work with mouse embryonic stem cells (ESCs) (12, 13). However, progress in generating a stem cell–based, DV patterned human NT model has been limited. A recent work shows 3D induction of dorsal, intermediate, and ventral spinal cord–like tissues from hPSCs in a free-floating cell aggregate culture system (14). However, this work falls short in demonstrating fully organized patterning of spinal cord–like tissues along the DV axis. The apical surface of spinal cord–like tissues derived in this work faces outside external environments (14), distinctly different from the NT in vivo. Together, it remains elusive whether hPSCs can be used to generate a human NT development model with full DV patterning.

In this study, we sought to develop a biomimetic 3D culture system mimicking the in vivo neurogenic niche for the development of an hPSC-based, DV patterned human NT development model. The biomimetic 3D culture incorporates some key in vivo neurogenic niche elements (15), including a 3D basal lamina extracellular matrix (ECM) to provide a permissive extracellular environment and a soft tissue bed to reconstruct the mechanical environment provided by the ventricular surface and ECM for the neuroepithelium during neurulation. This 3D biomimetic culture system allows convenient manipulations of dynamic interplays between chemical and biophysical signals that are critical for the cellular morphogenetic events and progressive neuronal fate specification during DV patterning of NT-like tissues derived from hPSCs. The development of the biomimetic 3D culture system, together with extrinsic exogenous biochemical signals delivered at precise timing and concentration, allows us to apply hPSCs to achieve the development of a human NT development model with full DV patterning. Our hPSC-based in vitro NT development model provides a valuable experimental tool for the analysis of human NT development and will contribute to researches on NT-related diseases and potentially to drug discovery and regenerative medicine.
RESULTS

3D biomimetic culture for NE cyst development

In the 3D biomimetic culture system, H9 hESCs were plated as single cells at $5 \times 10^3$ cells cm$^{-2}$ onto a thick, soft gel bed of Geltrex (with thickness of ≥100 μm and bulk Young’s modulus of ~900 Pa, coated on a glass coverslip) in mTeSR1 medium supplemented with the ROCK inhibitor Y27632 (Fig. 1, A and B). At 24 hours (day 1), a neurogenic environment was established by replacing mTeSR1 with fresh neural induction medium comprising N2B27 supplemented with 2% (v/v) Geltrex and SB431542 [SB; transforming growth factor–β (TGF-β) inhibitor] and LDN193189 [LDN; bone morphogenetic protein 4 (BMP4) inhibitor] (Fig. 1, A and B) ([16], [17]). To establish a 3D neural induction environment, 2% (v/v) Geltrex was further supplemented into the neural induction medium (hereinafter referred to as “Gel-3D”; Fig. 1, A and B). To assess the effects of ECM dimensionality and matrix rigidity, different modifications of the Gel-3D culture were conducted (Fig. 1B). First, glass coverslips coated with the soft gel bed were substituted with coverslips precoated with a thin layer of 1% Geltrex (hereinafter referred to as “Glass-3D”; Fig. 1B). Second, the 3D ECM overlay in Gel-3D was removed from the neural induction medium, with the gel bed retained on coverslips (hereinafter referred to as “Gel-2D”; Fig. 1B). Last, a standard 2D culture using glass coverslips precoated by 1% Geltrex was used (hereinafter referred to as “Glass-2D”; Fig. 1B).

Under neural induction condition in Glass-2D, hESCs exited pluripotency and differentiated into NE cells, evidenced by strong expression of PAX6, an early neuroectodermal marker, by day 8 (Fig. 1C). Immunostaining and immunoblotting of N-CADHERIN (N-CAD) at day 8 further confirmed successful neural conversion in Glass-2D (Fig. 1C and fig. S1, A and B). Confocal images recorded at day 8 show localized N-CAD expression at the top surface of NE cells in Glass-2D (Fig. S1A), suggesting the formation of the apical surface facing culture medium and the basolateral surface facing coverslip. Strikingly, in both Glass-3D and Gel-3D, while undergoing neural conversion with up-regulated PAX6 expression, hESCs self-assembled to form pseudostratified, multicellular cystic tissues.
enclosing a central lumen, with the N-CAD⁺ apical surface facing inward (Fig. 1, C and D). The luminal NE cyst in Glass-3D featured a flattened, pancake-shaped morphology, with a jagged outside surface accommodating expanding NE cells along the apical-basal axis (Fig. 1C and fig. S1A). In contrast, regular, spherical cystic tissues containing multilayered NE cells with smooth outside surfaces were evident in Gel-3D (Fig. 1, C and D). In Gel-2D, although hESCs clustered together as in Glass-3D and Gel-3D, the multicellular structures became irregular and discontinuous, with much fewer cells expressing PAX6 or N-CAD by day 8 (Fig. 1C and fig. S1, A and B), suggesting that Gel-2D was not as conducive as Glass-2D, Glass-3D, or Gel-3D for neural conversion. In Gel-2D, cystic tissues with irregular contour and elliptical contour constituted 63.01 ± 1.79% and 36.99 ± 1.79%, respectively, of all cystic tissues at day 8. The percentage of discontinuous cysts (cysts in which cells were missing in some areas) was 73.09 ± 2.20%. Moreover, multicellular structures in Gel-2D were smaller in size compared with those in Glass-2D, Glass-3D, or Gel-3D (Fig. 1C and fig. S1, A and C). We next investigated the development of NE cysts in Gel-3D with different gel bed thicknesses (fig. S1D). When the gel bed thickness decreased from 100 to 60 μm or 20 μm, which increased the effective substrate rigidity (18), although PAX6 expression was evident in all cysts, these cysts showed a flattened morphology with a jagged basal surface, similar to those cultured in Glass-3D (fig. S1D). Together, our data suggest that matrix rigidity might be an important factor mediating the formation of spherical NE cystic tissues.

Additional molecular characterizations were conducted for luminal NE cysts derived from H9 hESCs in Gel-3D. In addition to PAX6, NE cysts showed strong expression of SOX2 and NESTIN, another two neuroectodermal markers, at day 8. Neither SOX17, a definitive endoderm marker, nor BRACHYURY, CDX2, or EOMES, which are primitive streak and mesodermal markers, was detectable at day 8 (Fig. 1D and fig. S1E), excluding mesoderm or endoderm lineages in Gel-3D. SOX1, another neuroectodermal marker, was not detectable at day 8. However, continuous culture of NE cysts under neural induction condition in Gel-3D for another 5 days promoted SOX1 expression (Fig. 1E). Thus, PAX6 expression preceded SOX1 during the progressive development of NE cysts in Gel-3D, consistent with previous studies of neuroectodermal tissue developments from hPSCs (19) and human embryonic tissues (20). Further examination of ZO-1, a tight junction protein and apical polarity marker, confirmed the apical surface facing the central lumen in NE cysts (Fig. 1E). During the NT development in vivo, neural progenitor cells in the pseudostratified neuroepithelium undergo interkinetic nuclear migration (15), which results in mitotic cells localized at the apical surface and nuclei undergoing DNA synthesis (S phase) displaced more basally. Immunostaining for 5-ethynyl-2′-deoxyuridine (EdU) and phospho-histone H3 [pH3; a specific marker for mitosis (11)] at day 8 revealed that EdU-labeled S phase nuclei were preferentially located at the basal surface, whereas pH3⁺ mitotic cells were located closer to the apical surface (Fig. 1F).

**Progressive neural conversion in Gel-3D**

We next examined the dynamic progressive development of luminal NE cysts from H9 hESCs in Gel-3D. After initial cell seeding onto the gel bed, single H9 hESCs soon clustered together and formed individual small colonies (fig. S2, A and B). Soon after 3D ECM overlay was added at day 1, hESC colonies initiated the lumenogenesis program (21) and resolved into luminal cystic tissues while undergoing neural conversion. Within each well of a 24-well plate, 101.33 ± 1.67 individual NE cysts were formed by day 8. Multicellular cystic tissues in Gel-3D displayed rapid growth from day 1 to day 8, resulting in a 90-fold increase in their projected area over the 8-day period (fig. S2C).

Immunofluorescence analysis revealed that the exit of pluripotency and neural conversion of hESCs in Gel-3D occurred in a progressive, concurrent fashion (fig. S2D). Notably, all luminal cysts retained strong expression of OCT4 but without detectable PAX6 or N-CAD until day 4 (fig. S2, D and E). Emergence of PAX6 expression with concurrent loss of OCT4 was evident in a subset of lumenal cysts at day 6 (fig. S2, D and E). Specifically, at day 6, 16.50 ± 2.81% of lumenal cysts contained both OCT4⁺ and PAX6⁺ cells (fig. S2, D and E), suggesting neural conversion in progress. The percentage of lumenal cysts containing both OCT4⁺ and PAX6⁺ cells increased to 43.61 ± 4.23% at day 8 before decreasing to 6.07 ± 3.71% at day 10. By day 10, 93.93 ± 3.71% of lumenal cysts contained only PAX6⁺ NE cells without detectable OCT4⁺, suggesting completion of neural conversion (fig. S2, D and E). Western blotting for OCT4 and PAX6 at different days further confirmed the progressive, concurrent fashion of the exit of pluripotency and neural conversion of hESCs in Gel-3D during NE cyst development (fig. S2F).

**Default dorsal identity of NE cysts**

After specification of the neuroectoderm at the dorsal ectoderm germ layer, the development of the CNS continues with the acquisition of dorsal neural identity, revealed by expression of dorsal markers such as PAX3, PAX7, and MSX1/2 (14, 22, 23), by the midline dorsal ectodermal cells of the gastrulating embryo. Studies using mouse ESCs also show the default dorsal neural identity of NE cysts (12). We thus sought to examine the default dorsal or ventral fate of NE cysts derived from hESCs in Gel-3D. Immunostaining revealed that NE cysts uniformly expressed PAX6 at day 9 (Fig. 2, A and B). However, the dorsal neural marker PAX3 or MSX1 was not detectable at day 9 (Fig. 2B). Similarly, the ventral neural marker FOXA2, OLG2, or NKX2.2 was not detectable either at day 9 (Fig. 2B). NE cysts were further continuously cultured for another 9 days before immunofluorescence analysis to examine expression of dorsal and ventral neural markers. NE cysts at day 18 showed clear expression of PAX6, PAX3, and MSX1, with ventral neural markers FOXA2, OLG2, or NKX2.2 remaining undetectable (Fig. 2B). Together, these data show the default dorsal neural identity of NE cysts derived from hESCs, supporting a highly conserved default dorsal neural identity of the NT for vertebrates including humans.

**NE cysts are responsive to WNT and SHH signaling**

Dorsalization of the NT in vivo is mediated by a conserved signaling network involving BMP and WNT signals emanated from the neighboring non-neural ectoderm and the roof plate (1, 2, 24). To investigate whether NE cysts in Gel-3D would respond to WNT signaling for dorsal patterning, CHIR99021 (CHIR), a glycogen synthase kinase 3 (GSK3) inhibitor that functions as a WNT activator, was supplemented in neural induction medium from day 4 to day 9 (Fig. 2C). Immunofluorescence analysis revealed that most of NE cysts at day 9 showed PAX3 and MSX1 expression (Fig. 2D), supporting the effect of WNT activation on dorsalizing NE cysts. CHIR stimulation resulted in a regression of PAX6 expression within a confined region at the center of NE cysts (Fig. 2D), resembling the dorsal to ventral shift of PAX6 expression in the chick NT under WNT stimulations (25).
A sonic hedgehog (SHH) signaling gradient anti-parallel the DV axis emanated from the notochord and the floor plate (FP) has been shown critical for ventral patterning of the NT (1, 2, 24). During early ventral patterning of the NT, SHH signaling subdivides ventral NE cells into three main domains, namely, pMN, p3, and FP, along the DV axis (1, 2, 24). These ventral progenitor domains are identified by distinct transcription factors that further specify neuronal subtypes in each domain. The OLIG2+ pMN domain gives rise to motor neurons (MNs), whereas the NKKX2.2+ p3 and FOXA2+ FP domains generate V3 neurons and a glial structure, respectively (26). Current protocols for ventralizing NE cells rely on morphogens including SHH and retinoic acid (RA) (27). To achieve ventral patterning of NE cells in Gel-3D, we first activated SHH signaling by supplementing CHIR and ventralization with SAG, or RA and SAG, or RA, SAG, and SHH from day 4 to day 9. Bright-field images show representative NE cyst morphologies at day 9. (Fig. 2D). Together, these data suggest that specification of OLIG2+ pMN progenitor cells and FOXA2+ FP cells precedes the induction of NKKX2.2 p3 progenitor cells in Gel-3D.

**DV patterning of NE cysts**

Our data in Fig. 2 showed that although pMN, p3, and FP progenitor cells were induced by RA, SAG, and SHH in Gel-3D by day 9, ventral patterning of NE cysts with properly aligned pMN, p3, and FP domains was not achieved. To determine whether Gel-3D could support DV patterning of NE cysts, culture time was prolonged to 18 days, with RA (1 μM) and SAG (1 μM) or RA (1 μM) and SHH (either 10 or 100 nM) supplemented into neural induction medium from day 4 to day 9 (Fig. 3A). With RA and SAG, a small portion of NE cysts (<5%) displayed the key architectural feature of DV patterning at day 18, with ventral progenitor domains aligned adjacent to...
an induced FP region (Fig. 3, B and C). Specifically, in these patterned NE cysts, a single FOXA2+ FP domain emerged asymmetrically at one pole of the cyst (Fig. 3B). Adjacent to the FP, two NXX2.2+ p3 progenitor domains emerged in a symmetrical fashion (Fig. 3B). Two OLIG2+ pMN domains also simultaneously emerged dorsal to the two NXX2.2+ p3 domains (Fig. 3B). By day 18, PAX3+ dorsal NE cells became detectable and were restricted to the opposite pole of the OLIG2+ pMN domain (Fig. 3B), suggesting successful DV patterning of NE cysts under RA and SAG stimulation. The percentage of DV patterned NE cysts was significantly increased with SAG replacing SHH (10 or 100 nM) (Fig. 3C). Note that under this condition, most of the patterned NE cysts contained only one FP domain, with only 8.69 ± 0.66% of patterned NE cysts containing two or more FOXA2+ FP domains (Fig. 3D, A and B). In addition, the ventral pole of DV patterned NE cysts where the FOXA2+ FP was located appeared much thinner (Fig. 3D) and high levels of SHH signaling inhibit proliferation (29), leading to a much thinner FP region in the NT.

We confirmed that spherical PAX6+ NE cysts containing single central lumens could be derived from H1 hESC line and a hiPSC line (1196a) in Gel-3D under neural induction condition by day 8 (fig. S5, A and B). With RA and 10 nM SHH treatment from day 4 to day 9, proper DV patterned NE cysts were also achieved using H1 hESC line and 1196a hiPSC line in Gel-3D (Fig. 3F). Under RA and 100 nM SHH (Fig. 3, E and F). Under RA and 100 nM SHH, the percentage of ventral patterned NE cysts (27.03 ± 0.58%) with pMN and p3 progenitor domains properly aligned adjacent to an induced FP region was compatible to the value under RA and 10 nM SHH (Fig. 3F). However, very few PAX3+ dorsal cells were detected in NE cysts (Fig. 3E), suggesting an inhibitory effect on dorsal fate specification under this heightened ventralizing condition.

We next examined expression of other lineage markers associated with different ventral NT domains in NE cysts obtained under treatment with RA and 10 nM SHH (fig. S6A). DBX1 (a marker for p0 domain), DBX2 (a marker for p0 and p1 domains), or NXX6.2 (a marker for p1 domain) was not detectable at day 18. It is likely
that induction of these more dorsally localized domains might require other morphogen signals such as BMP or WNT, which are secreted by tissues adjacent to the NT in vivo. Around 20% of NE cysts showed localized expression of NKX6.1 (fig. S6B), a marker for the p3, pMN, and p2 domains (30, 31). The OLIG2⁺ pMN domain enclosed in the NKX6.1⁺ domain was observed in 22.27 ± 4.24% of NE cysts (fig. S6, B and C). We further observed mutually exclusive expression of NKX6.1 domain and FOXA2 domain in 13.6 ± 2.86% of NE cysts (fig. S6, B and C).

**Progressive DV patterning of NE cysts**

We next studied dynamic, progressive DV patterning of NE cysts by tracking spatiotemporal expression of dorsal and ventral markers, with NE cysts stimulated with RA (1 μM) and SHH (10 nM) from day 4 to day 9 (fig. 4). At day 9, all NE cysts contained PAX3⁺ dorsal cells but without any OLIG2⁺ pMN progenitor cells detectable (fig. 4, A and B). OLIG2⁺ cells started to emerge at day 12 in cyst regions where PAX3 expression was absent (fig. 4A). From day 14 to day 18, the percentage of NE cysts containing OLIG2⁺ cells continued to increase, whereas the PAX3 domain continuously became more restricted (fig. 4A). In a subset of NE cysts where OLIG2⁺ cells emerged as a cluster (the putative pMN domain) toward the prospective ventral pole of the cyst, concurrent, progressive restriction of the PAX3⁺ domain toward the opposite dorsal pole was evident (fig. 4A), suggesting dynamic progression of DV patterning regulated by RA and SHH through their dual effects on ventralization and antagonizing dorsalization (32). PAX3-OLIG2 DV polarity was established in 3.33 ± 1.33% of cysts at day 12, and this value increased at days 14 and 16 and reached 26.52 ± 5.34% at day 18 (Fig. 4, A and B).

We next tracked NKK2.2 and FOXA2 expression. At day 9, NKK2.2 was not detectable; however, 65.35 ± 2.79% NE cysts contained sparsely distributed FOXA2⁺ FP progenitor cells (fig. 4, C and D). At day 12, NKK2.2 remained undetectable; however, the percentage of NE cysts containing FOXA2⁺ cells decreased to 26.67 ± 1.76% (fig. 4, C and D). Notably, FOXA2⁺ cells appeared as a cluster (the putative FP domain) at the presumptive ventral pole at day 12 (fig. 4, C and D). NKK2.2 became detectable from day 14 onward, and its expression was evident only in cysts containing FOXA2⁺ cells (there was <4% cysts containing only NKK2.2⁺ cells at day 14; fig. 4, C and D). NE cysts (17.62 ± 2.23%) at day 14 displayed localized NKK2.2 domains dorsal to the FOXA2⁺ FP region (fig. 4, C and D), suggesting dynamic patterning of ventral domains. The percentage of these ventral patterned NE cysts increased to 46.18 ± 1.95% at day 18 (fig. 4, C and D).

**DV patterning of NE cysts by RA**

We next examined independent roles of RA and SHH in DV patterning of NE cysts. When only 1 μM RA was supplemented in neural induction medium from day 4 to day 9, 28.19 ± 2.31% of NE cysts achieved proper ventral patterning at day 18, with two NKK2.2⁺ p3 domains positioned dorsal to a single FOXA2⁺ FP domain (fig. 5, A and B). However, only 1.95 ± 0.05% of NE cysts showed PAX3-OLIG2 DV polarity, with PAX3⁺ dorsal cells located at the opposite pole of the OLIG2 pMN domain (fig. 5, A and B). When RA concentration was reduced to 0.1 μM, no patterned NE cyst was detectable (fig. 5, A and B). When stimulation with 1 μM RA was prolonged from day 4 to day 18, no patterned NE cyst was detectable either at day 18 (fig. 5C). FOXA2⁺ FP progenitor cells appeared uniformly at the cyst basal surface (fig. 5C). When treated with 0.1 μM RA from day 4 to day 18, 8.86 ± 1.18% of NE cysts showed PAX3-OLIG2 DV polarity (fig. 5, C and D). However, ventral patterning of NE cysts was not achieved because, although OLIG2⁺ pMN domains adjacent to FOXA2⁺ FP domain were evident in 27.08 ± 4.45% of NE cysts, the NKK2.2⁺ p3 domain was not detectable in any cyst (fig. 5, C and D). These results suggest that prolonged global RA stimulation might not be optimal for DV patterning. Together, these data suggest that optimal DV patterning of NE cysts depends on both RA concentration and the timing and duration of RA stimulation.

We next examined the independent effect of SHH. When only 10 nM SHH was supplemented in neural induction medium from day 4 to day 9, there was no distinct, localized FOXA2⁺ FP domain evident at day 18 (fig. 5E). FOXA2 expression remained dispersed in NE cysts, with only few OLIG2⁺ cells randomly distributed and no NKX2.2⁺ cells detectable (fig. 5E). We should note that most of the cysts collapsed and contained only multiple small lumens without a single central lumen by day 18 (fig. S7), suggesting that RA might have an important effect on maintaining the structural integrity of luminal NE cysts.

To further investigate RA-mediated DV patterning of NE cysts, cyclopamine (5 μM), an inhibitor of SHH signaling, was supplemented together with RA from day 4 to day 9 (fig. 5F). In the presence of cyclopamine, FOXA2⁺, NKK2.2⁺, or OLIG2⁺ ventral cells were undetectable at day 18, with only a few PAX3⁺ dorsal cells evident (fig. 5F). We further performed qualitative real-time polymerase chain reaction (qRT-PCR) to confirm the effect of cyclopamine. With cyclopamine, PAX3 expression was significantly upregulated, whereas expression of OLIG2, NKK2.2, FOXA2, and SHH was significantly down-regulated (fig. 5G). Together, these data support the role of SHH signaling in the ventralizing effect of RA.

Our observation of RA-mediated DV patterning of NE cysts is consistent with previous studies on mouse NE cysts (12, 33), suggesting a conserved general patterning mechanism by RA.

**Anterior-posterior positional identity of NE cysts**

Previous studies have shown that prolonged dual inhibition of activin and BMP signaling specifies hESCs toward an anterior neuroectodermal identity (34). Thus, NE cysts developed in Gel-3D under the neural induction condition might have an anterior identity. In addition to its role in DV patterning, RA has a posteriorizing effect on the NT in vitro (35). It is well established that RA regulates progressive HOX gene activation to establish regional identities in the posterior hindbrain and cervical spinal cord (35). Thus, we next evaluated the positional identity of NE cysts along the anterior-posterior (A-P) axis, with or without RA supplemented in neural induction medium from day 4 to day 9 (fig. S8A). qRT-PCR was conducted to assess expression of region-specific markers along the A-P axis at day 18. In RA-treated NE cysts, expression of FOXG1 (forebrain marker), OTX2 (forebrain/midbrain marker), and HOX A2 (expressed in the r2 of the hindbrain) was significantly down-regulated (fig. S8B). Expression of GBX2, a midbrain/hindbrain marker (36), was not affected by RA treatment (fig. S8B). Expression of HOX B4, a cervical spinal cord marker, was significantly increased in RA-treated NE cysts (fig. S8B). The anterior border of HOXB4 is at the r6/r7 boundary of hindbrain (36). Thus, our qRT-PCR analysis suggests that RA-treated NE cysts have a positional identity of the posterior hindbrain and the cervical spinal cord.

**Generation of MNs from NE cysts**

After DV patterning of the NT, different progenitor domains of the NT will continue to develop and specify region-specific neuronal...
Fig. 4. Dynamics of DV patterning of NE cysts in Gel-3D. (A) Representative confocal micrographs showing cysts stained for PAX3 and OLIG2 at different days as indicated. (B) Pie charts showing percentages of different types of cysts at different days as indicated. Cysts were grouped into five categories as indicated (PAX3+OLIG2−, PAX3−OLIG2−, PAX3+OLIG2+ patterned, PAX3+OLIG2+ unpatterned, and PAX3+OLIG2+). (C) Representative confocal micrographs showing cysts stained for NKX2.2 and FOXA2 at different days as indicated. (D) Pie charts showing percentages of different types of cysts at different days as indicated. Cysts were grouped into five categories as indicated (NKX2.2−FOXA2+, NKX2.2−FOXA2−, NKX2.2+FOXA2+ patterned, NKX2.2+FOXA2+ unpatterned, and NKX2.2+FOXA2+). Data in (B) and (D) represent the mean. A total of 150 cysts were counted from n = 3 independent experiments at each time point. Scale bars, 50 μm (A and C).
Fig. 5. Independent effects of RA and SHH on patterning of NE cysts in Gel-3D. (A) Effect of RA stimulation (1 or 0.1 μM) alone from day 4 to day 9. Representative confocal micrographs show cysts at day 18 stained for dorsal and ventral markers as indicated. (B) Percentages of different patterned cysts as a function of RA dose. Data represent means ± SEM. Fifty cysts were counted from each independent experiment. n = 3 independent experiments at each RA dose. (C) Effect of RA stimulation (1 or 0.1 μM) alone from day 4 to day 18. Representative confocal micrographs show cysts at day 18 stained for dorsal and ventral markers as indicated. (D) Percentages of different patterned cysts as a function of RA dose. Data represent means ± SEM. Fifty cysts were counted from each independent experiment. n = 3 independent experiments at each RA dose. (E) Effect of SHH stimulation alone from day 4 to day 9. Representative confocal micrographs show cysts at day 18 stained for dorsal and ventral markers as indicated. (F) Effect of inhibition of SHH signaling with cyclopamine from day 4 to day 9. Representative confocal micrographs show cysts at day 18 stained for dorsal and ventral markers as indicated. (G) qRT-PCR analysis of PAX3, OLIG2, NKX2.2, FOXA2, and SHH expression for cysts at day 18 with or without cyclopamine treatment. Data are normalized against GAPDH and represent means ± SEM. n = 3 independent experiments. P values were calculated using unpaired two-tailed Student’s t test. *P < 0.05, **P < 0.01, and ***P < 0.001. Scale bars, 50 μm (A, C, D, and E).
subtypes in each domain. The OLIG2− pMN domain will give rise to MNs. We thus sought to specify OLIG2+ pMN progenitor cells in NE cysts into MNs. Our data in Fig. 2D showed an effective induction of OLIG2+ pMN progenitor cells in NE cysts by supplementing RA and SAG from day 4 to day 9 (Fig. 6A). At day 9, neuronal progenitor cells with characteristic neuronal morphology and expression of neuronal markers βIII-TUBULIN and MAP2 were evident in NE cysts (Fig. 6B). After continuous culture of NE cysts in neural induction medium for another 9 days, by day 18, numerous neurites were evident extending into the surrounding environment from the cyst basal surface as detected by immunostaining for βIII-TUBULIN and MAP2 (Fig. 6B). There were a few cells even migrating out of NE cysts (Fig. 6B). NE cysts at day 18 contained a few cells expressing ISLET1/2 (MN-associated transcription factor); however, no HB9+ cells were detectable (HB9 is an MN-specific transcription factor), suggesting incomplete MN specification.

We next added neurotrophic factors brain-derived neurotrophic factor (BDNF; 10 ng ml−1), glial-derived neurotrophic factor (GDNF; 10 ng ml−1), ciliary neurotrophic factor (CNTF; 10 ng ml−1), insulin-like growth factor–1 (IGF-1; 10 ng ml−1), cyclic adenosine monophosphate (cAMP; 1 μM), and ascorbic acid (AA; 0.2 μg ml−1) into neural induction medium from day 9 onward (Fig. 6C). BDNF is a member of neurotrophin family and is required for the differentiation and survival of specific neuronal subpopulations (37). GDNF increases

---

**Fig. 6. Induction of spinal MNs from NE cysts in Gel-3D.** (A and B) Induction of spinal MNs with RA and SAG supplemented from day 4 to day 9. Representative confocal micrographs in (B) show cysts at days 9 and 18 stained for βIII-TUBULIN, MAP2, ISLET1/2, and HB9 as indicated. DAPI counterstained nuclei. (C and D) Induction of spinal MNs with RA and SAG supplemented from day 4 to day 9 and neurotrophic factors BDNF, GDNF, CNTF, IGF-1, cAMP, and AA supplemented from day 9 to day 18. Representative confocal micrographs in (D) show cysts at day 18 stained for ISLET1/2, MAP2, HB9, and βIII-TUBULIN as indicated. DAPI counterstained nuclei. The zoomed-in image shows a magnified view of the area highlighted by the white square. (E and F) Induction of spinal MNs with RA and SHH supplemented from day 4 to day 9 and neurotrophic factors from day 12 to day 25. Representative confocal micrographs in (F) show cysts at day 25 stained for FOXA2, OLIG2, HB8, and ISLET1/2. (G) Percentage of different patterned cysts. Data represent means ± SEM. n_cyst = 126 and 134 for HB9 staining and ISLET1/2 staining, respectively. n = 3 independent experiments. Scale bars, 50 μm (B, D, and F).
proliferation of MN progenitor cells and promotes neuronal differentiation and survival (38). CNTF is important for the survival of MNs (39), whereas IGF-1 promotes differentiation and survival of MNs (40). When these growth factors are used together in vitro, they have been shown to be effective in driving hPSC-derived neuronal progenitor cells into MNs (41). At day 18, extensive MAP2+ and βIII-TUBULIN+ neurites were evident extending from the cyst basal surface, and there were ISLET1/2+ and HB9+ neuronal cells migrating out of NE cysts (Fig. 6D). There were ISLET1/2 HB9+ MNs evident at the cyst peripheral region (Fig. 6D), suggesting successful MN specification.

ISLET1/2 HB9+ MNs are derived from the pMN domain and localized at the ventral part of the NT in vivo. To further examine whether ISLET1/2 HB9+ MNs developed in patterned NE cysts were derived from the pMN domain, we applied RA and SHH as DV patterning signals from day 4 to day 9 before neurotrophic factors were implemented at day 12 (Fig. 6E). Excitingly, at day 25, about 17% of NE cysts contained HB9+ and ISLET1/2+ MNs at the cyst basal region adjacent to the OLG2+ pMN domain (Fig. 6, F and G), suggesting that HB9+ and ISLET1/2+ MNs were developed from the pMN domain in NE cysts.

**DISCUSSION**

As the embryonic precursor to the CNS, the NT generates distinct classes of neuronal progenitor cells located at defined positions within the NT through intricate patterning events. Considerable progress has been made in determining the signaling activities and genetic networks that control region-specific neuronal fate patterning in the NT (1, 2, 24). It is now appreciated that acquisition of a specific neuronal fate depends on the position of precursor NE cells within the NT, which defines their exposure to inductive morphogens that gradually constrain their developmental potential in each local domain. Morphogens instructing DV patterning of the NT include WNTs, BMPs, and SHH, with WNT and BMP emanated from the dorsal ectoderm and roof plate, favoring dorsal identities, and SHH emanated from the notochord, inducing ventral identity (1, 2, 24). In this work, we have established the neurogenic Gel-3D culture that promotes hPSCs to self-organize into spherical, lumenal NE cysts, mimicking the development of the NT tissue in vivo. The intrinsic laminogenic property of hPSCs prompts the cells to undergo lumenogenesis in Gel-3D to form a central apical lumen (Fig. S2) (21). Under the neural induction environment, hPSCs in the lumenal cyst exit pluripotency and progress along the neural lineage while continuing to divide (Fig. S2). By day 9, NE cysts emerge in Gel-3D, featuring a single central lumen with correct apicobasal polarity, displaying interkinetic nuclear migration and pseudostratification, and expressing early neuroectodermal markers including PAX6, SOX2, SOX1, NESTIN, and N-CAD (Fig. 1). NE cysts at day 9 appear to correspond to an early stage of the neural plate formation in the dorsal ectoderm germ layer. Our data show that both ECM dimensionality and matrix rigidity are critical extracellular microenvironmental factors for proper development of NE cysts from hPSCs. In particular, a 3D culture environment is required for the development of 3D cystic NE tissues enclosing a central lumen (Fig. 1C). Consistent with previous studies on mouse NE tissues (12, 13), hESC-derived NE cysts have a default dorsal neural identity (Fig. 2, A and B), supporting a conserved default dorsal neural identity of the NT for vertebrates including humans.

NE cysts derived from hPSCs in Gel-3D are responsive to morphogen stimulations (Fig. 2C), opening the door to modulating exogenous morphogen signals for achieving region-specific neuronal fate patterning. Excitingly, under proper DV patterning conditions, NE cells within lumenal cysts differentiate into region-specific progenitors in discrete local domains and achieve cell fate patterning along the DV axis (Fig. 3). Progressive development of NE cysts features sequential emergence of neural progenitor domains, with the ventral FP, P3, and pMN domains emerging progressively in discrete, non-overlapping regions and the PAX3+ dorsal territory progressively restricted to the opposite, prospective dorsal pole (Fig. 4). The OLG2+ pMN domain in DV patterned NE cysts can be further specified into ISLET1/2 HB9+ MNs (Fig. 6).

In the Gel-3D culture, DV patterning of hPSC-derived NE cysts appears to initiate after removal of exogenous morphogen signals (Fig. 4). This observation may be related to the hysteresis property of SHH signaling, in which intracellular SHH signaling remains active after withdrawal of exogenous morphogens (42). Previous studies using mouse NT explants suggest that the transcriptional network for ventral patterning of the NT can produce hysteresis, providing NE cells in the NT with a memory of SHH signaling even when extracellular signaling gradients recede (43). Our data further suggest a role of intracellular SHH signaling in the ventralizing effect of RA (Fig. 5). This observation is consistent with previous studies of the effect of RA on NE tissues derived from mouse ESCs, which have shown induction of SHH by RA administration and consequently expression of ventral NT markers (12). In vivo, both the notochord and FP secrete RA (24), and it has been suspected that RA may act as a permissive signal for SHH-mediated ventral patterning of the NT (12). Thus, it is likely that supplementation of RA in our system promotes SHH signaling, which, in turn, induces the specification of FOXA2+ FP progenitor cells.

It remains puzzling how global applications of exogenous morphogens lead to the formation of a local FOXA2+ FP domain. Our temporal immunofluorescence data suggest that at the initial phase of DV patterning, FOXA2+ FP progenitor cells emerge in a scattered fashion at the basal surface of NE cysts. Soon thereafter, FOXA2 expression becomes restricted to a local prospective FP region at the putative ventral pole of NE cysts. This observation suggests a likely involvement of a self-enhancing activator/inhibitor signaling system, leading to a single localized FP region formation. This hypothesis warrants future investigation.

In this work, we have successfully derived DV patterned NT-like tissues from hPSCs. Nonetheless, it remains a considerable challenge (and thus a future goal) to obtain NT-like tissues containing all progenitor domains along the DV axis. In vivo, DV patterning of the NT involves multiple morphogen gradients emanated from neighboring signaling centers located at different anatomical regions. Our current Gel-3D system applies global administrations of exogenous morphogens. It remains a future goal to integrate neural induction of hPSCs with advanced microfluidic systems to introduce well-defined, dynamic parallel and antiparallel morphogen gradients to achieve full DV patterning of NT-like tissues. Our DV patterned NT development model offers great opportunities for experimental control of key parameters and quantitative measurements, providing an advantageous experimental platform for advancing our understanding of the emergent self-organizing principles and patterning mechanisms that provide robustness and reliability to NT DV patterning, a long-standing question in biology. Patterned NT-like tissues
derived from hPSCs are also useful for the development of stem cell–based regenerative therapies, disease models, and screening applications for diagnosis, prevention, and treatment of neurological disorders that are resulted from impairments of the development and growth of the CNS system.

**MATERIALS AND METHODS**

**Cell culture**

hESC line H9 [WA09, WiCell; National Institutes of Health (NIH) registration number: 0062], H1 (WA01, WiCell; NIH registration number: 0043), and 1196a hiPSC line (from the University of Michigan Pluripotent Stem Cell Core) were cultured under a standard feeder-free condition in mTeSR1 medium (STEMCELL Technologies) with daily medium exchange. Cells were passaged every 5 days using dispase (STEMCELL Technologies) and the StemPro EZPassage Disposable Stem CellPassaging Tool (Invitrogen). Cell pellets resuspended in mTeSR1 were transferred onto a six-well tissue culture plate (BD Biosciences) precoated with 1% lactate dehydrogenase–elevating virus (LDEV)–free hESC-qualified reduced growth factor basement membrane matrix Geltrex (Thermo Fisher Scientific). All cell lines used in this study had a passage number of <P70, and they were authenticated as karyotypically normal by Cell Line Genetics. H9 hESC line was tested negative for mycoplasma contamination (LookOut Mycoplasma PCR Detection Kit, Sigma-Aldrich).

**Fabrication of gel beds**

Geltrex gel bed was generated on the basis of a “sandwich” scheme developed recently for inducing amniogenesis from hPSCs (5). In brief, two 12-mm-diameter round glass coverslips were treated with air plasma (Harrick Plasma) for 2 min. One of the coverslips, which was to be coated with the gel bed, was soaked in poly-(L-lysine) solution (0.1 mg ml⁻¹) (Sigma-Aldrich) for 30 min and then in 1% glutaraldehyde solution (Electron Microscopy Sciences) for another 30 min. The other coverslip was coated with poly-(L-lysine)-graft-poly-(ethylene glycol) (PLL-g-PEG, 0.1 mg ml⁻¹; SuSoS) solution for 1 hour. To obtain gel beds with nominal thickness of 20, 60, and 100 μm, undiluted Geltrex (10, 30, and 50 μl, respectively) was then added to the two coverslips on ice before being incubated at 37°C for 30 min. The glass coverslip coated with the Geltrex gel bed was then gently separated from the PLL-g-PEG–coated coverslip before being submerged in Dulbecco’s modified Eagle’s medium (DMEM)/F12 medium (Thermo Fisher Scientific) and incubated at 37°C overnight before plating cells at the following day.

**Neural induction**

hPSC colonies were first treated with Accutase (Sigma-Aldrich) for 10 min at 37°C. Cells were rinsed briefly with phosphate-buffered saline (PBS) before being collected, centrifuged, and resuspended in mTeSR1 containing the ROCK inhibitor Y27632 (10 μM; Tocris). Singly dissociated hPSCs were plated onto coverslips at an initial cell seeding density of 50 × 10⁶ cells cm⁻² and cultured overnight. For Gel-2D and Gel-3D cultures, the coverslip was precoated with the Geltrex gel bed, whereas for Glass-2D and Glass-3D conditions, glass coverslips were precoated with 1% Geltrex solution for 1 hour at room temperature. On the following day (day 1), culture medium was switched to fresh N2B27-based neural induction medium (see below). For Gel-3D and Glass-3D conditions, this neural induction medium contained 2% (v/v) Geltrex. Thereafter, fresh neural induction medium with or without 2% (v/v) Geltrex supplement was exchanged daily.

N2B27-based neural induction medium comprised Advance DMEM/F12 (Gibco): Neurobasal medium (1:1; Gibco), 0.5× N2 (Gibco), 0.5× B27 (Gibco), 1× nonessential amino acids (Gibco), 2 mM l-glutamine (Gibco), and 0.1 mM β-mercaptoethanol (Sigma-Aldrich). N2B27-based neural induction medium further contained the TGF-β pathway inhibitor SB (10 μM; STEMCELL Technologies) and the BMP inhibitor LDN (0.1 μM; STEMCELL Technologies).

For dorsalization of NE cysts, 3 μM CHIR (STEMCELL Technologies) was supplemented into neural induction medium from day 4 to day 9. For ventralization of NE cysts, all-trans RA (1 μM; STEMCELL Technologies), recombinant human SHH (10 or 100 nM; PeproTech), and/or SAG (1 μM; STEMCELL Technologies) were supplemented into neural induction medium from day 4. For MN induction, the following chemicals were added to neural induction medium from day 9 or day 12: BDNF (10 ng ml⁻¹; R&D Systems), GDNF (10 ng ml⁻¹; PeproTech), CNTF (10 ng ml⁻¹; PeproTech), IGF-1 (10 ng ml⁻¹; PeproTech), cAMP (1 μM; Sigma-Aldrich), and AA (0.2 μg ml⁻¹; Sigma-Aldrich).

**Immunocytochemistry**

Cystic tissues were fixed in 4% paraformaldehyde (Electron Microscopy Sciences) at room temperature for 1 hour before being permeabilized with 0.1% SDS (dissolved in PBS) solution at room temperature for 3 hours. Cysts were then blocked in 10% goat serum solution (Thermo Fisher Scientific) or 4% donkey serum solution (Sigma-Aldrich) at 4°C overnight. Immunostaining was performed in primary antibody solutions prepared in blocking buffer for 24 hours at 4°C. Cysts were then washed with PBS and incubated with goat- or donkey-raised secondary antibodies at 4°C for another 24 hours. DAPI (4′,6-diamidino-2-phenylindole; Invitrogen) was used for counterstaining cell nuclei. All primary antibodies, their sources, and dilutions are listed in table S1. For EdU incorporation, NE cysts at day 8 were incubated with EdU for 1 hour and fixed thereafter. EdU was detected using the Click-iT EdU Alexa Fluor 488 Imaging Kit (Thermo Fisher Scientific).

**qRT-PCR analysis**

Total RNA was isolated from untreated hPSCs or NE cysts using the RNeasy Micro Kit (Qiagen). RNA quality and concentration were detected using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). RNA was reverse-transcribed using the iScript cDNA Synthesis Kit (Bio-Rad). qRT-PCR was performed with QuantiTect SYBR Green Master Mix (Qiagen) and gene-specific primers on the CFX Connect Real-Time System (Bio-Rad). Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous control for quantifying relative gene expression by calculating 2−ΔΔCT with the corresponding SEM. All analyses were performed with at least three biological replicates. Primers used in this work are listed in table S2.

**Confocal microscopy and image analysis**

Images were recorded using an Olympus DSU1X81 fluorescence microscope with a CSU-X1 spinning disc unit (Yokogawa). 3D reconstructed cyst images were obtained using ImageJ (NIH).

**Western blotting**

Whole-cell lysates were extracted from cells before being homogenized by sonication. SDS–polyacrylamide gel electrophoresis (SDS-PAGE) was used for separation of proteins, which were then transferred onto polyvinylidene difluoride (PVDF) membranes. PVDF membranes were stained with Coomassie Brilliant Blue R-250 (Thermo Fisher Scientific) and destained with destaining solution (20% acetic acid, 10% methanol). Membranes were washed with 1× TBS and used for Western blotting.
were incubated with blocking buffer (Li-Cor) for 3 hours and then with primary antibodies (table S1) overnight at 4°C. Blots were incubated with IRDye secondary antibodies (Li-Cor) for 3 hours at room temperature. Protein expression was detected by the Odyssey Sa Infrared Imaging System (Li-Cor).

Statistical analysis
All data are shown as means ± SEM. Statistical analysis on the qRT-PCR data was performed using two-sided unpaired Student’s t tests in Excel (Microsoft). P < 0.05 was considered statistically significant.

SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/...


Acknowledgments

Funding: This work was supported by the University of Michigan Mechanical Engineering Faculty Support Fund (to J.F.), the Michigan-Cambridge Research Initiative (to J.F.), and the University of Michigan Mcubed Fund (to J.F.). A.M.R.I. is partially supported by the National Science Foundation Graduate Research Fellowship under grant no. DGE 1256260. Author contribution: Yuanjuan Zheng, G.Z., and J.F. conceived and initiated the project. Yuanjuan Zheng and X.X. designed, performed, and analyzed most of the experiments. A.M.R.I., Z.L., Y.S., and Yi Zheng helped design and perform experiments and image and data analyses. Yuanjuan Zheng, X.X., G.Z., and J.F. wrote the manuscript. G.Z. and J.F. supervised the study. All authors edited and approved the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Submitted 5 April 2019
Accepted 9 October 2019
Published 11 December 2019
10.1126/sciadv.aax5933

Dorsal-ventral patterned neural cyst from human pluripotent stem cells in a neurogenic niche
Y. Zheng, X. Xue, A. M. Resto-Irizarry, Z. Li, Y. Shao, Y. Zheng, G. Zhao and J. Fu

Sci Adv 5 (12), eaax5933.
DOI: 10.1126/sciadv.aax5933